Differential inhibition of human cytomegalovirus (HCMV) by toll-like receptor ligands mediated by interferon-beta in human foreskin fibroblasts and cervical tissue.
Human cytomegalovirus (HCMV) can be acquired sexually and is shed from the genital tract. Cross-sectional studies in women show that changes in genital tract microbial flora affect HCMV infection and/or shedding. Since genital microbial flora may affect HCMV infection or replication by stimulating cells through Toll-like receptors (TLR), we assessed the effects of defined TLR-ligands on HCMV replication in foreskin fibroblasts and ectocervical tissue. Poly I:C (a TLR3-ligand) and lipopolysaccharide (LPS, a TLR4-ligand) inhibited HCMV and induced secretion of IL-8 and Interferon-beta (IFNbeta) in both foreskin fibroblasts and ectocervical tissue. The anti-HCMV effect was reversed by antibody to IFNbeta. CpG (TLR9 ligand) and lipoteichoic acid (LTA, TLR2 ligand) also inhibited HCMV infection in ectocervical tissue and this anti-HCMV effect was also reversed by anti-IFNbeta antibody. In contrast, LTA and CpG did not inhibit HCMV infection in foreskin fibroblasts. This study shows that TLR ligands induce an HCMV-antiviral effect that is mediated by IFNbeta suggesting that changes in genital tract flora may affect HCMV infection or shedding by stimulating TLR. This study also contrasts the utility of two models that can be used for assessing the interaction of microbial flora with HCMV in the genital tract. Clear differences in the response to different TLR ligands suggests the explant model more closely reflects in vivo responses to genital infections.
Harwani
Sailesh C
SC
Department of Immunology/Microbiology, Rush University, Chicago, USA. Sailesh_harwani@hotmail.com
Lurain
Nell S
NS
Zariffard
M Reza
MR
Spear
Gregory T
GT
D002478:Cells, Cultured; D002584:Cervix Uteri / Q000187:drug effects / Q000821:virology*; D003587:Cytomegalovirus / Q000187:drug effects*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000821:virology; D052816:Foreskin / Q000187:drug effects / Q000378:metabolism / Q000821:virology*; D006801:Humans; D016899:Interferon-beta / Q000096:biosynthesis / Q000276:immunology*; D016209:Interleukin-8 / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism; D008024:Ligands; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D011070:Poly I-C / Q000494:pharmacology*; D051193:Toll-Like Receptors / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism*; D017201:Virus Shedding
D016209:Interleukin-8; D008024:Ligands; D008070:Lipopolysaccharides; D051193:Toll-Like Receptors; D016899:Interferon-beta; D011070:Poly I-C